ABV101
Diabetes Management (Hypoglycemia Prevention)
Pre-clinicalActive
Key Facts
Indication
Diabetes Management (Hypoglycemia Prevention)
Phase
Pre-clinical
Status
Active
Company
About Abvance Therapeutics
Abvance Therapeutics is a private, pre-clinical-stage biotech focused on revolutionizing diabetes management. Its core innovation is a combination therapy (ABV101) that pairs insulin with glucagon to proactively prevent hypoglycemia, aiming to free patients from the constant fear of low blood sugar crashes and enable better glycemic control. The company, founded in 2020, is built on a deeply personal mission and scientific foundations from Vanderbilt University, and is currently advancing its lead candidate toward clinical development while seeking strategic partnerships.
View full company profile